Delving into the Latest Updates on Shenzhen Lingfang Biomedical Technology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Lifang Biotech, an innovative company focused on the research and development of anti-tumor targeted drugs. The company's core R&D team has decades of experience in research and development of new drugs at home and abroad. Since its establishment, the company has rapidly introduced a number of new anti-tumor targeted drugs, fully considered the organic combination of drug performance and innovative mechanism, and established a unique pipeline combination.

Tags

Neoplasms

Digestive System Disorders

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Immune System Diseases	2
Hemic and Lymphatic Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

FGFRs(Fibroblast growth factor receptors)	1
ATR(Serine-protein kinase ATR)	1

主要目的：1、评估剂量限制性毒性（DLT）的发生情况，以确定最大耐受剂量（MTD）和/或Ⅱ期推荐剂量（RP2D）2、评估联合方案的安全性和耐受性次要目的：1、评价SC0011和阿帕替尼的药代动力学特征 2、评价SC0011联合阿帕替尼对晚期胃癌/胃食管结合部腺癌患者中的初步有效性 3、评估FGFR2过表达或扩增与疗效的相关性。

[Translation]

Main purposes: 1. Evaluate the occurrence of dose-limiting toxicities (DLT) to determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) 2. Evaluate the safety and tolerability of the combination regimen Secondary purposes: 1. To evaluate the pharmacokinetic characteristics of SC0011 and apatinib 2. To evaluate the preliminary effectiveness of SC0011 combined with apatinib in patients with advanced gastric cancer/gastroesophageal junction adenocarcinoma 3. To evaluate the overexpression of FGFR2 or the correlation between amplification and efficacy.

Start Date08 Jan 2024

Sponsor / Collaborator

Shenzhen Lingfang Biomedical Technology Co., Ltd.

CTR20221402 / RecruitingPhase 1

评价LF0397片在晚期实体瘤患者中的安全性、耐受性、药代动力学特征及初步有效性的开放、多中心、Ia期临床试验

[Translation] An open-label, multicenter, phase Ia clinical trial evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of LF0397 tablets in patients with advanced solid tumors

主要目的评价LF0397片的安全性和耐受性；确定LF0397片的最大耐受剂量（MTD）（如有）和后续研究的合适推荐剂量。次要目的评价LF0397片的药代动力学特征；评价LF0397片的初步抗肿瘤疗效。

[Translation]

main purpose To evaluate the safety and tolerability of LF0397 tablets; To determine the maximum tolerated dose (MTD) of LF0397 tablets, if available, and appropriate recommended doses for follow-up studies. secondary purpose To evaluate the pharmacokinetic characteristics of LF0397 tablets; The preliminary antitumor efficacy of LF0397 tablets was evaluated.

Start Date30 Jun 2022

Sponsor / Collaborator

Shenzhen Lingfang Biomedical Technology Co., Ltd.

CTR20220594 / RecruitingPhase 1

评价LF0376片单药治疗结直肠癌、胰腺癌、肝癌等晚期实体瘤和淋巴瘤患者安全性、有效性及药代动力学特征的开放、多中心、Ia期临床研究

[Translation] An open-label, multicenter, phase Ia clinical study evaluating the safety, efficacy and pharmacokinetics of LF0376 tablets as a monotherapy in patients with colorectal cancer, pancreatic cancer, liver cancer and other advanced solid tumors and lymphomas

主要目的： 1、评价LF0376片的安全性和耐受性； 2、确定LF0376片的最大耐受剂量（MTD）和后续研究的合适推荐剂量（RD）。次要目的： 1、评价LF0376片的药代动力学（PK）特征； 2、初步评价LF0376片治疗结直肠癌、胰腺癌、肝癌等晚期实体瘤和淋巴瘤患者的有效性

[Translation]

main purpose: 1. Evaluate the safety and tolerability of LF0376 tablets; 2. Determine the maximum tolerated dose (MTD) of LF0376 tablets and the appropriate recommended dose (RD) for follow-up studies. Secondary purpose: 1. To evaluate the pharmacokinetic (PK) characteristics of LF0376 tablets; 2. Preliminary evaluation of the efficacy of LF0376 tablets in the treatment of colorectal cancer, pancreatic cancer, liver cancer and other advanced solid tumors and lymphoma patients

Start Date20 Jun 2022

Sponsor / Collaborator

Shenzhen Lingfang Biomedical Technology Co., Ltd.

100 Clinical Results associated with Shenzhen Lingfang Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Lingfang Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Shenzhen Lingfang Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Lingfang Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

2

3

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LF-0376	Colorectal Cancer More	Phase 1
SC-0011 ( FGFRs )	Advanced gastric carcinoma More	Phase 1
LF0397 ( ATR )	Solid tumor More	Phase 1
LF0001 ( KRAS G12C )	Lung Cancer More	IND Approval
LF0315	Tumor of advanced extent More	IND Approval